Intentar ORO - Gratis
Innovation – The next frontier
Express Pharma
|October 2020
Alok Ghosh, Ex-President - Global Technical Operations, Lupin, underscores the importance of creating a conducive environment to foster innovation in India’s life sciences sector to ensure its continuous progress
The USFDA recently is-sued a guideline titled product Launch Notification under Section 506I. The guideline instructs companies to let the USFDA know if a product is not launched even after 180 days of getting approval. USFDA felt the need to issue this guideline on product launch since data shows that only about 40 per cent of generic products are getting launched after USFDA approval within a year. This means about 60 per cent of products are not getting launched after USFDA approval even after a year. The data also shows that even after five years about 30 per cent of products are not getting launched. Pharma companies spend a lot of money on development, bio studies, filing of product and pay GDUFA fees. Then, why are the products not launched even after approval? The answer is that there are way too many competitors marketing the same product thereby reducing the scope of marketing or the cost of the product is prohibitive to selling the product at a competitive price.
Essentially two developments have happened in the last couple of years:
1. The USFDA stepped up approval of products by introducing GDUFA and inducted a lot of new inspectors/reviewers to clear the backlogs of approval. From a backlog of more than 36 months once, one can expect approval of new product now in 12-14 months if the quality of filing and data is acceptable. This helped in more generic products getting approval, throwing the US market into intense competition.
2. The market consolidated in the US and from about 10-12 buyers, today about 90 per cent of buying are controlled effectively by three buyers only, namely – Red Oak, Walgreen- Boots Alliance & McKesson. This means the buyers have now very high bargaining power bringing price pressure on marketed products. It is now a win-win situation for both, the government and consumers in the US.
Esta historia es de la edición October 2020 de Express Pharma.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Express Pharma
Express Pharma
Glass vs other pharma packaging materials: Safeguarding purity, enhancing trust
Rajesh Khosla, CEO, AGI Greenpac explains why glass stands out as a trusted material that continues to meet modern pharma's safety and sustainability demands
3 mins
March 2026
Express Pharma
WHEN She LEADS
Women shaping pharma today share honest lessons and real-world leadership wisdom for the next generation of women who dare to lead
15 mins
March 2026
Express Pharma
Our approach is to combine localised production with global quality standards
Jean Charles Wirth, Global CEO of Merck Life Science, shares insights on the company's approach in a price conscious and quality focused market like India, the company's close alignment with the 'Make in India' vision and how Merck is fostering scientific talent to support customers in India, the Asia-Pacific region, and globally, in an interaction with Viveka Roychowdhury
3 mins
March 2026
Express Pharma
India has the infrastructure to lead the global gene therapy market
Professor Philip J. Young, Director of Educational Analytics, School of Life Sciences, University of Warwick, outlines how AI is compressing drug discovery timelines, why affordability remains the real bottleneck in SMA care, and how India can lead the next phase of precision medicine, in an exclusive interview with Neha Aathavale
8 mins
March 2026
Express Pharma
Industrial and infrastructure sectors are undergoing rapid modernisation
In the pharma sector, precision is non-negotiable and compliance is constant. Attention often focuses on formulations and manufacturing processes; yet the foundation of operational excellence lies in infrastructure - the systems that quietly ensure safety, efficiency and regulatory adherence. Jinali Gandhi, Director at Gandhi Automations, represents a new generation of leaders shaping this critical dimension of the industry
2 mins
March 2026
Express Pharma
Targeted incentives for innovation-driven research would further strengthen India's biotech ecosystem
Venkat Nelabhotla, Co-Founder, President and CEO of Vyome Holdings, shares how focused innovation, disciplined development and policy support can accelerate India's emergence as a global biotech innovation hub, in an interview with Lakshmipriya Nair
3 mins
March 2026
Express Pharma
Partners in Progress: PPL 2026
PPL 2026 brought together India's pharma packaging ecosystem to explore how collaboration, innovation, and technical expertise can strengthen patient safety, product stability, and operational efficiency. Across partner-led sessions, speakers discussed how structured systems, material science, regulatory alignment, and technology integration collectively elevate packaging from a support function to a strategic enabler.
2 mins
March 2026
Express Pharma
What truly differentiates Transchem is our technical-first approach
Sanjay Lanke, VP - Technical Business Development, Transchem Corporation Pharma, outlines its focus on innovation, strategic partnerships, and portfolio diversification to support complex formulations while expanding its presence across pharma, nutraceutical, and food ingredient markets, in an interview with Lakshmipriya Nair
3 mins
March 2026
Express Pharma
Tech, trust and traceability: Shaping India pharma's future
At the PPL Conclave 2026, hosted by Express Pharma, industry leaders explored how innovation, operational excellence and evolving regulations are positioning packaging as a strategic driver in India's pharma growth, reports Neha Aathavale
7 mins
March 2026
Express Pharma
In 2026, India serves as the reliable 'technical engine' for global research
Dr Seema Pai, President, Indian Society for Clinical Research outlines how India's clinical research landscape is evolving into a quality-driven, innovation-led ecosystem, supported by regulatory progress, digital adoption, and stronger patient-centric approaches positioning the country as a global research hub, in an interview with Swati Rana
6 mins
March 2026
Translate
Change font size
